| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany
TCR-driven clonal expansion of T cells is limited by activation-induced cell death through CD95/CD95L interactions. This cell-contact dependent mechanism is attenuated by costimulation through CD28. Here, we show that primary rat lymph node T cells activated by "superagonistic" CD28-specific mAb, which do not require TCR-engagement for full T cell activation, do not up-regulate CD95L. CD28 superagonist activated T cells are highly resistant to artificial CD95 cross-linking, and display a marked up-regulation of the survival factor Bcl-xL. Consistently, NF-
B factors, known to promote Bcl-xL transcription, are strongly activated by superagonistic CD28 mAb stimulation. In contrast, a weaker induction of NFAT, which positively regulates the CD95L gene, in CD28 activated cells as compared with TCR- or TCR/CD28-stimulated cells was observed. Thus, by recruiting the mitogenic activity of CD28 in the absence of TCR engagement, the anti-apoptotic signals provided by costimulation are revealed without interfering proapoptotic effects induced by TCR stimulation.
This article has been cited by other articles:
|
|
 |
|
  A. Serra, S. Nuti, S. Tavarini, C. Sammicheli, D. Rosa, G. Saletti, E. Soldaini, S. Abrignani, and A. Wack Coligation of the Hepatitis C Virus Receptor CD81 with CD28 Primes Naive T Lymphocytes to Acquire Type 2 Effector Function J. Immunol., July 1, 2008; 181(1): 174 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Dennehy, F. Elias, S.-Y. Na, K.-D. Fischer, T. Hunig, and F. Luhder Mitogenic CD28 Signals Require the Exchange Factor Vav1 to Enhance TCR Signaling at the SLP-76-Vav-Itk Signalosome J. Immunol., February 1, 2007; 178(3): 1363 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kerstan, N. Armbruster, M. Leverkus, and T. Hunig Cyclosporin A Abolishes CD28-Mediated Resistance to CD95-Induced Apoptosis via Superinduction of Caspase-3 J. Immunol., December 1, 2006; 177(11): 7689 - 7697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Legrand, T. Cupedo, A. U. van Lent, M. J. Ebeli, K. Weijer, T. Hanke, and H. Spits Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2-/-{gamma}c-/- mice Blood, July 1, 2006; 108(1): 238 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Beyersdorf, T Hanke, T Kerkau, and T Hunig Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv91 - iv95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beyersdorf, S. Gaupp, K. Balbach, J. Schmidt, K. V. Toyka, C.-H. Lin, T. Hanke, T. Hunig, T. Kerkau, and R. Gold Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis J. Exp. Med., August 1, 2005; 202(3): 445 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Frankenberger, H. Pohla, E. Noessner, G. Willimsky, B. Papier, A. Pezzutto, J. Kopp, R. Oberneder, T. Blankenstein, and D. J. Schendel Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs Clin. Cancer Res., March 1, 2005; 11(5): 1733 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lun, P. L. Zhang, P. K. Pellitteri, A. Law, T. L. Kennedy, and R. E. Brown Nuclear Factor-kappaB Pathway as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma: Pharmaceutical and Molecular Validation in Human Cell Lines Using Velcade and siRNA/NF-{kappa}B. Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
